Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Jubilant To Acquire Draxis Health | Contract Pharma

What are you searching for?

Sign in
Breaking News

Jubilant To Acquire Draxis Health

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Jubilant Organosys Ltd. and Draxis Health, Inc. have entered into an agreement whereby Jubilant will acquire all outstanding common shares of Draxis for approximately $255 million.
   
Mr. Shyam S. Bhartia, chairman and managing director of Jubilant, and Mr. Hari S. Bhartia, co-chairman and managing director of Jubilant, commented, “Draxis represents a unique opportunity in the North American market, offering Jubilant entry into the attractive, regulated, high growth and high margin radiopharmaceutical business. It also enables Jubilant to consolidate its position in the sterile and non-sterile contract manufacturing business. With this acquisition Jubilant will become one of the leading providers of contract manufacturing of small volume parenterals to large pharmaceuticals and biotech companies in North America. Jubilant is committed to grow Draxis by supporting management and employees through new product launches, entry into new markets and expansion of customer base.”
   
Under the agreement, Draxis, in certain circumstances, can terminate the arrangement and accept an unsolicited superior proposal, subject to fulfilling certain conditions. Draxis has agreed to pay Jubilant a break fee of $10.5 million in such circumstances and certain other limited circumstances if the transaction is not completed. The transaction, subject to customary closing conditions, is expected to close in 2Q08.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics